A New No-Lyse, No-Wash Flow-Cytometric Method for the Determination of CD4 T Cells in Blood Samples

2003 ◽  
Vol 30 (1) ◽  
pp. 8-13 ◽  
Author(s):  
B. Greve ◽  
U. Cassens ◽  
C. Westerberg ◽  
W. Göhde jun. ◽  
W. Sibrowski ◽  
...  
2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A873-A873
Author(s):  
Arika Feils ◽  
Mackenzie Heck ◽  
Anna Hoefges ◽  
Peter Carlson ◽  
Luke Zangl ◽  
...  

BackgroundMice bearing B78 melanoma tumors can be cured using an in situ vaccine (ISV) regimen that includes radiation (RT) together with immunocytokine (tumor-targeting mAb conjugated to IL-2). B78 melanoma cells, derived from B16 cells, express minimal to no MHC-I but express MHC-II upon IFN-g/TNF-a stimulation. Although B78 cells are primarily MHC-I-deficient, an increased CD8 T cell infiltration into the tumor microenvironment (TME) has been shown following ISV.1 To further investigate the potential role of specific immune cell lineages in the B78 anti-tumor response to ISV, immune subset depletion studies and flow cytometric analyses were performed.MethodsC57BL/6 mice bearing B78 tumors were depleted of immune cell subsets with mAbs (anti-CD4, anti-CD8, anti-NK1.1, or Rat IgG control) for 3 weeks during the course of treatment. Treatment groups included no treatment, RT (12 Gy), or ISV (RT D0 and immunocytokine D5-D9). 6 mice/group (repeated three times) were followed for survival/tumor growth, and flow cytometry studies included 4 mice/group, sacrificed on D8 and D13 following the start of ISV.ResultsMice depleted of CD4 T cells during the course of ISV showed a significant reduction of anti-tumor effect as compared to mice treated with ISV/Rat IgG (pConclusionsThese studies suggest that CD4 T cells are essential for an anti-tumor response in the B78 melanoma model. In vivo depletion data show that CD4 T cells, but not CD8 or NK cells, are required for a decrease in tumor growth via ISV. Flow cytometric analyses suggest an interplay between CD4 and CD8 T cells as indicated by a decrease in CD8/IFN-g expression following ISV in the absence of CD4 T cells. The role that MHC-I and MHC-II expression plays in this CD4/CD8 T cell anti-tumor response is under investigation. In future studies, B78 melanoma may serve as a critical syngeneic model for development of more effective immunotherapy treatment regimens.Ethics ApprovalAll animal experiments were performed in accordance with protocols approved by Animal Care and Use Committees of the University of Wisconsin-Madison.ReferenceMorris Z, Guy E, Francis D, et al. In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments. Cancer Res 2016;76(13):3929-3941.


Immunity ◽  
2009 ◽  
Vol 30 (1) ◽  
pp. 155-167 ◽  
Author(s):  
Gang Wei ◽  
Lai Wei ◽  
Jinfang Zhu ◽  
Chongzhi Zang ◽  
Jane Hu-Li ◽  
...  

Cytometry ◽  
1998 ◽  
Vol 33 (1) ◽  
pp. 76-82 ◽  
Author(s):  
Jan Storek ◽  
Monja A. Dawson ◽  
David G. Maloney

2004 ◽  
Vol 50 (1) ◽  
pp. 59-66 ◽  
Author(s):  
Shiro Tochizawa ◽  
Seiji Akamatsu ◽  
Yoshihiro Sugiyama ◽  
Masahiro Muraguchi ◽  
Yasukazu Ohmoto ◽  
...  

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4494-4494
Author(s):  
Rachel Elizabeth Cooke ◽  
Jessica Chung ◽  
Sarah Gabriel ◽  
Hang Quach ◽  
Simon J. Harrison ◽  
...  

Abstract The average incidence of multiple myeloma (MM) is in the 7th decade that coincides with the development of immunosenescence and thymic atrophy, meaning that lymphocyte recovery after lymphopenia-inducing therapies (most notably autologous stem cell transplant, ASCT) is largely reliant on homeostatic proliferation of peripheral T cells rather than replenishing the T cell pool with new thymic emigrants. We have previously shown that there is a significant reduction in circulating naïve T cells with a reciprocal expansion of antigen-experienced cells from newly diagnosed MM (NDMM) to relapsed/refractory disease (RRMM). This results in a reduced TCR repertoire and the accumulation of senescence-associated secretory phenotype cytotoxic T cells, which maintain the ability to produce IFNγ but lose proliferative potential. A reduction in CD4:8 ratio is also a characteristic finding in MM with disease progression, which can be explained by high IL-15 levels in lymphopenic states that preferentially drive expansion of CD8+ memory T cells. We wanted to further evaluate what changes were occurring in the CD4+ T cell population with disease progression in MM. We analyzed paired peripheral blood (PB) samples from patients with NDMM and RRMM, and compared with age-matched normal donors (ND). In the NDMM cohort, we examined T cells from PB samples at baseline, after 4 cycles of lenalidomide and dexamethasone (len/dex), and after ASCT; and in the RRMM cohort samples from baseline and after 6 cycles of len/dex. We firstly confirmed in flow cytometric analysis of T cells at serial intervals in NDMM patients that the reduction in circulating naïve T cells and in CD4:8 ratio occurs post ASCT and does not recover by time of last follow-up. We next utilised RNA-seq to analyse differences in CD4+ T cells from NDMM, RRMM and ND. CD4+ T cells from RRMM showed downregulation of cytosolic ribosomal activity but maintenance of mitochondrial ribosomal activity and significant upregulation of pathways involved with calcium signalling. To this end, we evaluated mitochondrial biogenesis and metabolic pathways involved with mitochondrial respiration. Flow cytometric analysis of mitochondrial mass showed a marked increase in RRMM compared with ND, in keeping with a shift towards memory phenotype. Key rate-limiting enzymes in fatty acid β-oxidation (CPT1-A, ACAA2 and ACADVL) were all significantly increased in RRMM compared with ND. To analyse whether these cells were metabolically active, we also measured mitochondrial membrane potential and reactive oxygen species (ROS), gating on cells with high mitochondrial mass. Mitochondrial membrane potential was significantly increased in RRMM compared with ND, although ROS was reduced. The significance of this is not clear, as ROS are not only implicated in cell senescence and activation-induced cell death, but are also positively involved in tyrosine kinase and PI3K-signalling pathways. PD-1 has been shown to play a role in transitioning activated CD4+ T cells from glycolysis to FAO metabolism, and elevating ROS in activated CD8+ T cells. We analysed PD-1 expression on T cells in RRMM and at treatment intervals in NDMM (as described earlier). The proportion of CD4+ and CD8+ T cells expressing PD-1 was increased 4-6 months post-ASCT and remained elevated in CD4+ T cells 9-12 months post-ASCT, but normalised to baseline levels in CD8+ T cells. Increased PD-1 expressing CD4+ T cells was also evident in RRMM patient samples. This may suggest that in the lymphopenic state, PD-1 expression enhances longevity in a subset of CD4+ T cells by promoting reliance on mitochondrial respiration; however, their ability to undergo homeostatic proliferation is impaired. In CD8+ T cells, high PD-1 expression may lead to cell death via ROS accumulation, and these cells do not persist. ASCT remains a backbone of myeloma treatment in medically fit patients. However, this leads to significant permanent defects in the T cell repertoire, which may have unintended adverse outcomes. Additionally, T cells post-ASCT may not be metabolically adequate for the production of CAR-T cells, nor respond to checkpoint blockade therapies. Disclosures Quach: Amgen: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Sanofi Genzyme: Research Funding; Janssen Cilag: Consultancy. Harrison:Janssen-Cilag: Other: Scientific advisory board. Prince:Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees.


1998 ◽  
Vol 5 (6) ◽  
pp. 745-748 ◽  
Author(s):  
Sandrine Kahi ◽  
Grégoire J. N. Cozon ◽  
Timothy Greenland ◽  
Martine Wallon ◽  
Françoise Gay-Andrieu ◽  
...  

ABSTRACT To assess cell-mediated immunity to Toxoplasma gondii, we evaluated the expression of the activation antigens CD69, CD71, and CD25 on T lymphocytes by flow cytometry after specific in vitro stimulation of whole blood from 127 T. gondii-positive and 63 T. gondii-negative patients. T lymphocytes from many seropositive individuals did not express CD69 at 24 h afterT. gondii antigen stimulation, but CD71 and CD25 were easily detectable on T cells from seropositive individuals 7 days after specific activation. CD25 was mainly expressed by stimulated CD4+ T cells, and its detection on total T cells was both a sensitive (98%) and a specific (97%) indicator of prior T. gondii infection. These results make flow cytometric detection of CD25 an excellent candidate for screening cell-mediated immunity toT. gondii in vitro and an interesting tool for the diagnosis of congenital infection.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 1516-1516
Author(s):  
Yusuke Higuchi ◽  
Jun-ichirou Yasunaga ◽  
Yu Mitagami ◽  
Koichi Ohshima ◽  
Masao Matsuoka

Human T-cell leukemia virus, type 1 (HTLV-1) causes adult T-cell leukemia-lymphoma (ATL) and chronic inflammatory diseases (e.g., HTLV-1 associated myelopathy, uveitis). Among viral genes encoded in the HTLV-1 provirus, HTLV-1 bZIP factor (HBZ) is the most important gene for its pathogenesis, since HBZ is constantly expressed in all ATL cases, and has a potential to enhance T-cell proliferation. We generated HBZ transgenic (Tg) mice and found that almost all mice developed systemic inflammation, such as dermatitis, and about 40% of mice suffered from T-cell lymphoma. In addition, this mouse demonstrates the similar immunophenotypes to HTLV-1-infected subjects, such as increase of effector/memory and Foxp3-expressing regulatory T cells (Tregs), indicating that it is a good animal model to analyze the molecular mechanisms of pathogenesis by HTLV-1. There is a clear correlation between the severity of inflammation and the incidence of T-cell lymphoma, suggesting that some immune factors are closely involved in oncogenesis by HBZ. Recent studies showed that several pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-6 (IL-6), participate in not only inflammation but also tumor development. Especially, IL-6 has been reported to play important roles in oncogenesis, tumor progression, angiogenesis and migration. To clarify the roles of IL-6 in HBZ-mediated lymphomagenesis, we crossed HBZ-Tg mice with IL-6 knockout (KO) mice. Contrary to our hypothesis, inflammation was exacerbated, and incidence of T-cell lymphomas was markedly increased in HBZ-Tg/IL-6KO mice. In the pathological analysis of the lymphoma tissues, the percentage of Foxp3+ cells were much higher in HBZ-Tg/IL-6KO mice than in HBZ-Tg mice. Moreover, flow cytometric analysis also showed that CD4+Foxp3+ T cells were increased in spleens from HBZ-Tg/IL-6KO mice compared with HBZ-Tg mice or WT mice. Since IL-6 inhibits TGF-beta-induced Foxp3 expression and subsequently suppresses differentiation to Tregs, our results suggest that depletion of IL-6 induces aberrant differentiation of CD4+ T cells toward Treg-like cells in HBZ-Tg mice and accelerates lymphomagenesis of this subset. RNA-seq and flow cytometric analyses revealed that expression of IL-10 was significantly higher in CD4+ T cells of HBZ-Tg/IL-6KO than HBZ-Tg. Importantly, IL-10 accelerated the proliferation of CD4+ T cells of HBZ-Tg whereas it did not influence control T cells. We also found that HBZ interacted with both STAT1 and STAT3, which are critical transcription factors in IL-10-JAK/STAT signaling pathways, and enhanced their transcriptional activities. Foxp3-expressing T cells and IL-10 are known to be immune-suppressive, but these results indicate that increased Foxp3-expressing T cells and activation of IL-10-JAK/STAT signaling are associated with inflammation and lymphomagenesis by HBZ in vivo. Our results suggest that IL-6 and IL-10 have suppressive and promoting effects on HBZ-induced pathogenesis, respectively. It has been reported that progression of HTLV-1-associated diseases was observed in several HTLV-1 carriers after administration of anti-IL-6R antibody, Tocilizumab. Inhibition of IL-6/IL-6R signaling and consequent activation of Foxp3/IL-10/JAK/STAT axis seem to be important for HTLV-1 pathogenesis. Disclosures Ohshima: Kyowa Kirin Co., Ltd.: Honoraria, Research Funding; Chugai Pharmaceutical Co., Ltd.: Honoraria, Research Funding; Celgene Corp.: Honoraria, Research Funding; NEC Corp.: Research Funding; SRL, Inc.: Consultancy. Matsuoka:Kyowa Kirin Co., Ltd.: Research Funding; Bristol-Myers Squibb Corp.: Research Funding; Chugai Pharmaceutical Co., Ltd.: Honoraria.


2001 ◽  
Vol 251 (1-2) ◽  
pp. 101-108 ◽  
Author(s):  
Anne Marie Asemissen ◽  
Dirk Nagorsen ◽  
Ulrich Keilholz ◽  
Anne Letsch ◽  
Alexander Schmittel ◽  
...  
Keyword(s):  
T Cells ◽  

Sign in / Sign up

Export Citation Format

Share Document